Curated News
By: NewsRamp Editorial Staff
August 04, 2025
XOMA Royalty to Acquire LAVA Therapeutics in Landmark Biotech Deal
TLDR
- XOMA Royalty's acquisition of LAVA Therapeutics offers shareholders a cash advantage of $1.16 to $1.24 per share plus a 75% net proceeds CVR from partnered assets.
- XOMA Royalty will acquire LAVA Therapeutics through a tender offer by August 15, 2025, subject to shareholder approval and customary closing conditions.
- This transaction supports the advancement of gamma delta bispecific antibodies, promising significant benefits for patients with acute myeloid leukemia and myelodysplastic syndrome.
- LAVA Therapeutics' Gammabody® platform, targeting CD33 and EGFR, is at the heart of this acquisition, highlighting innovative approaches to treating hematologic and solid tumors.
Impact - Why it Matters
This acquisition is a pivotal moment in the biotech industry, combining XOMA Royalty's financial acumen with LAVA Therapeutics' innovative cancer treatments. It promises to accelerate the development of therapies that could significantly improve patient outcomes, particularly in oncology. For investors, the deal offers a unique opportunity to partake in the potential upside of LAVA's partnered and unpartnered programs through the CVR. Beyond the financial implications, this collaboration underscores the importance of strategic partnerships in bringing cutting-edge medical solutions to market faster, benefiting patients worldwide.
Summary
XOMA Royalty Corporation and LAVA Therapeutics N.V. have announced a definitive share purchase agreement, marking a significant step in the biotechnology sector. Under the agreement, XOMA Royalty will acquire LAVA for a cash amount ranging between $1.16 and $1.24 per share, plus a non-transferable contingent value right (CVR) that could further benefit shareholders. This strategic move is aimed at leveraging LAVA's innovative gamma delta bispecific antibodies, which are poised to make a substantial impact in treating various cancers. The deal, endorsed by both companies' leadership, underscores a shared vision for advancing healthcare solutions and maximizing shareholder value. The transaction is expected to close in the fourth quarter of 2025, following a tender offer and shareholder approval.
The collaboration highlights the potential of combining XOMA Royalty's expertise in royalty aggregation with LAVA Therapeutics' pioneering Gammabody® platform. This platform has already fostered partnerships with industry giants like Johnson & Johnson and Pfizer, targeting hematologic cancers and solid tumors, respectively. The acquisition not only signifies a milestone for both entities but also sets the stage for accelerated development and commercialization of groundbreaking therapies. With the backing of top-tier legal and financial advisors, this deal is a testament to the vibrant innovation and strategic partnerships driving the biotech industry forward.
Source Statement
This curated news summary relied on content disributed by citybiz. Read the original source here, XOMA Royalty to Acquire LAVA Therapeutics in Landmark Biotech Deal
